Sign up to save your podcasts
Or
Share Why ASO Technology?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Why ASO Technology?
What makes antisense oligonucleotides (ASOs) so special?
Let’s first understand what an oligonucleotide is. An oligonucleotide is a short strand of synthetic DNA or RNA (a nucleic-acid chain), usually consisting of up to approximately 20 nucleotides long—designed to bind with specific sequences in the body.
At n-Lorem, our ASO technology is built on more than 30 years of research, innovation, and investment. It’s uniquely suited for treating nano-rare diseases—ultra-rare genetic conditions that affect just one or a few individuals. The versatility and specificity of ASOs allow us to address a wide variety of gene mutations, creating customized therapies for each unique patient.
Compared to other traditional drug discovery platforms, discovering and developing an optimal ASO is inexpensive, quick and can be used to treat diseases that are caused by many different types of gene mutations. ASOs work by binding to RNA, thereby modifying the expression of disease-causing proteins. This makes them exceptionally well-suited for treating diseases caused by rare or unique genetic mutations.
On This Episode We Discuss:
- The repurposing of small molecule drugs
- The promise and limitations of gene replacement therapies
- What makes ASO drug development different—and better—for nano-rare diseases
- A brief history of modern drug development
- How regulatory frameworks evolved after medical disasters
- The decentralization of the biotechnology industry
- What challenges still lie ahead in genetic medicine
Intro to Medical Science Series YouTube Playlist: https://www.youtube.com/playlist?list=PLrDVyc3t26Fy5aQpo3mulackGlUwrIqYL
View all episodes
By n-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen)
5
3030 ratings
What makes antisense oligonucleotides (ASOs) so special?
Let’s first understand what an oligonucleotide is. An oligonucleotide is a short strand of synthetic DNA or RNA (a nucleic-acid chain), usually consisting of up to approximately 20 nucleotides long—designed to bind with specific sequences in the body.
At n-Lorem, our ASO technology is built on more than 30 years of research, innovation, and investment. It’s uniquely suited for treating nano-rare diseases—ultra-rare genetic conditions that affect just one or a few individuals. The versatility and specificity of ASOs allow us to address a wide variety of gene mutations, creating customized therapies for each unique patient.
Compared to other traditional drug discovery platforms, discovering and developing an optimal ASO is inexpensive, quick and can be used to treat diseases that are caused by many different types of gene mutations. ASOs work by binding to RNA, thereby modifying the expression of disease-causing proteins. This makes them exceptionally well-suited for treating diseases caused by rare or unique genetic mutations.
On This Episode We Discuss:
- The repurposing of small molecule drugs
- The promise and limitations of gene replacement therapies
- What makes ASO drug development different—and better—for nano-rare diseases
- A brief history of modern drug development
- How regulatory frameworks evolved after medical disasters
- The decentralization of the biotechnology industry
- What challenges still lie ahead in genetic medicine
Intro to Medical Science Series YouTube Playlist: https://www.youtube.com/playlist?list=PLrDVyc3t26Fy5aQpo3mulackGlUwrIqYL
More shows like Patient Empowerment Program: A Rare Disease Podcast
View all
This American Life
90,949 Listeners
Embedded
12,026 Listeners
The Daily
111,917 Listeners
Crime Junkie
366,047 Listeners
The Readout Loud
318 Listeners
The Weekly Show with Jon Stewart
10,613 Listeners
BioSpace
10 Listeners